Arcutis Biotherapeutics, Inc. (ARQT) Form 8-K — Jul 16, 2026
$ARQTForm 8-KItems 5.02, 7.01, 9.01Filed Jul 16, 2026, 4:25 PM ET0001628280-26-048469Original filing
Arcutis Biotherapeutics has expanded its Board of Directors from nine to ten members and appointed Christopher Peetz as a new independent Class III director. Mr. Peetz, who currently serves as CEO of Mirum Pharmaceuticals, will hold his seat until the 2029 annual meeting of stockholders. In accordance with the company's compensation program, Mr.
Key figures
- Board Size
- increased from 9 to 10
- Annual Cash Retainer
- $50,000
- Annual Equity Award Value
- $350,000
- Initial Option Award Shares
- 21486
Price after filing
1 day: +2.7%7 days: -1.5%30 days: -5.6%
Close on the filing date to close N calendar days later (from $27.74). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.